A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)

Richard B Pollard, Camlin Tierney, Diane Havlir, Pablo Tebas, Lawrence Fox, Laura Smeaton, Douglas Richman, Gerald H. Friedland

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Before the development of multidrug regimens for treatment of patients with HIV infection single or dual nucleoside therapy was the standard of care. The present study was designed to examine the relative short (12-week) and long-term (48-week) activity of zidovudine (ZDV) vs stavudine (d4T) vs the combination in antiretroviral naive patients. The study was modified so that lamivudine (3TC) was added to ZDV after 12 weeks of monotherapy. A total of 129 subjects entered the study; however, not all were followed for 48 weeks as the study was terminated early due to changing standards of care. The median baseline viral load and CD4 cell count were 10,008 copies/ml and 407 cells/mm3, respectively. There were no significant differences in the initial (12-week) change in viral load across the three arms. The viral load reduction at 48 weeks was greater in the ZDV/ZDV plus 3TC arm, with an average change of -0.91 log10 copies/ml than in the d4T alone (-0.47 log10 copies/ml) or d4T plus ZDV (-0.33 log10 copies/ml), p = 0.03 and 0.02, respectively. There was a marginally significant increase in the CD4 cell count at Week 12 in the d4T arm as compared to the ZDV/ZDV plus 3TC arm. In general the treatments were well tolerated. The combination of d4T plus ZDV did not result in additional antiviral suppression as compared to either drug alone at 12 weeks and appeared to have less antiviral activity after Week 12. Based on this study and other data, combining d4T and ZDV is not recommended.

Original languageEnglish (US)
Pages (from-to)699-704
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume18
Issue number10
DOIs
StatePublished - 2002

Fingerprint

Stavudine
Lamivudine
Zidovudine
Viral Load
Standard of Care
CD4 Lymphocyte Count
Antiviral Agents
Nucleosides
HIV Infections
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). / Pollard, Richard B; Tierney, Camlin; Havlir, Diane; Tebas, Pablo; Fox, Lawrence; Smeaton, Laura; Richman, Douglas; Friedland, Gerald H.

In: AIDS Research and Human Retroviruses, Vol. 18, No. 10, 2002, p. 699-704.

Research output: Contribution to journalArticle

@article{2412f1ee50bc40a4a2228481571ead4a,
title = "A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)",
abstract = "Before the development of multidrug regimens for treatment of patients with HIV infection single or dual nucleoside therapy was the standard of care. The present study was designed to examine the relative short (12-week) and long-term (48-week) activity of zidovudine (ZDV) vs stavudine (d4T) vs the combination in antiretroviral naive patients. The study was modified so that lamivudine (3TC) was added to ZDV after 12 weeks of monotherapy. A total of 129 subjects entered the study; however, not all were followed for 48 weeks as the study was terminated early due to changing standards of care. The median baseline viral load and CD4 cell count were 10,008 copies/ml and 407 cells/mm3, respectively. There were no significant differences in the initial (12-week) change in viral load across the three arms. The viral load reduction at 48 weeks was greater in the ZDV/ZDV plus 3TC arm, with an average change of -0.91 log10 copies/ml than in the d4T alone (-0.47 log10 copies/ml) or d4T plus ZDV (-0.33 log10 copies/ml), p = 0.03 and 0.02, respectively. There was a marginally significant increase in the CD4 cell count at Week 12 in the d4T arm as compared to the ZDV/ZDV plus 3TC arm. In general the treatments were well tolerated. The combination of d4T plus ZDV did not result in additional antiviral suppression as compared to either drug alone at 12 weeks and appeared to have less antiviral activity after Week 12. Based on this study and other data, combining d4T and ZDV is not recommended.",
author = "Pollard, {Richard B} and Camlin Tierney and Diane Havlir and Pablo Tebas and Lawrence Fox and Laura Smeaton and Douglas Richman and Friedland, {Gerald H.}",
year = "2002",
doi = "10.1089/088922202760072311",
language = "English (US)",
volume = "18",
pages = "699--704",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)

AU - Pollard, Richard B

AU - Tierney, Camlin

AU - Havlir, Diane

AU - Tebas, Pablo

AU - Fox, Lawrence

AU - Smeaton, Laura

AU - Richman, Douglas

AU - Friedland, Gerald H.

PY - 2002

Y1 - 2002

N2 - Before the development of multidrug regimens for treatment of patients with HIV infection single or dual nucleoside therapy was the standard of care. The present study was designed to examine the relative short (12-week) and long-term (48-week) activity of zidovudine (ZDV) vs stavudine (d4T) vs the combination in antiretroviral naive patients. The study was modified so that lamivudine (3TC) was added to ZDV after 12 weeks of monotherapy. A total of 129 subjects entered the study; however, not all were followed for 48 weeks as the study was terminated early due to changing standards of care. The median baseline viral load and CD4 cell count were 10,008 copies/ml and 407 cells/mm3, respectively. There were no significant differences in the initial (12-week) change in viral load across the three arms. The viral load reduction at 48 weeks was greater in the ZDV/ZDV plus 3TC arm, with an average change of -0.91 log10 copies/ml than in the d4T alone (-0.47 log10 copies/ml) or d4T plus ZDV (-0.33 log10 copies/ml), p = 0.03 and 0.02, respectively. There was a marginally significant increase in the CD4 cell count at Week 12 in the d4T arm as compared to the ZDV/ZDV plus 3TC arm. In general the treatments were well tolerated. The combination of d4T plus ZDV did not result in additional antiviral suppression as compared to either drug alone at 12 weeks and appeared to have less antiviral activity after Week 12. Based on this study and other data, combining d4T and ZDV is not recommended.

AB - Before the development of multidrug regimens for treatment of patients with HIV infection single or dual nucleoside therapy was the standard of care. The present study was designed to examine the relative short (12-week) and long-term (48-week) activity of zidovudine (ZDV) vs stavudine (d4T) vs the combination in antiretroviral naive patients. The study was modified so that lamivudine (3TC) was added to ZDV after 12 weeks of monotherapy. A total of 129 subjects entered the study; however, not all were followed for 48 weeks as the study was terminated early due to changing standards of care. The median baseline viral load and CD4 cell count were 10,008 copies/ml and 407 cells/mm3, respectively. There were no significant differences in the initial (12-week) change in viral load across the three arms. The viral load reduction at 48 weeks was greater in the ZDV/ZDV plus 3TC arm, with an average change of -0.91 log10 copies/ml than in the d4T alone (-0.47 log10 copies/ml) or d4T plus ZDV (-0.33 log10 copies/ml), p = 0.03 and 0.02, respectively. There was a marginally significant increase in the CD4 cell count at Week 12 in the d4T arm as compared to the ZDV/ZDV plus 3TC arm. In general the treatments were well tolerated. The combination of d4T plus ZDV did not result in additional antiviral suppression as compared to either drug alone at 12 weeks and appeared to have less antiviral activity after Week 12. Based on this study and other data, combining d4T and ZDV is not recommended.

UR - http://www.scopus.com/inward/record.url?scp=0036063917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036063917&partnerID=8YFLogxK

U2 - 10.1089/088922202760072311

DO - 10.1089/088922202760072311

M3 - Article

VL - 18

SP - 699

EP - 704

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 10

ER -